Menu
- syed.nasar@daneenbio.com
- +91-9321378847
BIOLOGICS
- Vaccines, allergenics, somatic cells, blood and blood components, recombinant therapeutic proteins and a wide variety of products which are isolated from natural sources including human, animals or microorganisms are categorised under Biologics.
- At this point, the Indian biologics market is dominated by simple biologics including insulin, erythropoietin, drugs for cardiovascular and autoimmune disease, monoclonal antibodies among others.
- The Indian government is promoting biotech-based drug development with various approaches in terms of fundings and investments. Initiatives under ‘Making in India’ campaigns are favourable enough for the Indian pharma industry. Department of Biotechnology (DBT), Biotechnology Industry Research Assistance Council (BIRAC), union health ministry and Indian Council of Medical Research (ICMR) are some of the main governing bodies actively encouraging India’s biotech sector with various initiatives. Such bodies also motivate Public Private Partnerships (PPP) to attract investments for biotech business.
- Opportunities presented by manufacturing capabilities, labour availability and low development cost can make a huge difference for Indian biologics business in coming years.
- In terms of structure, most biologics are complex mixtures as compared to conventional drugs and as biologics represent the cutting-edge of biomedical research, biologics have the potential to offer the most effective treatment for a wide range of diseases and conditions which were incurable with conventional medicines.
Previous
Next